The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature
Top Cited Papers
Open Access
- 28 March 2024
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 143 (13) , 1269-1281
Abstract
Acute myeloid leukemia (AML) is a hematologic malignancy for which allogeneic hematopoietic cell transplantation (allo-HCT) often remains the only curative therapeutic approach. However, incapability of T cells to recognize and eliminate residual leukemia stem cells might lead to an insufficient graft-versus-leukemia (GVL) effect and relapse. Here, we performed single-cell RNA-sequencing (scRNA-seq) on bone marrow (BM) T lymphocytes and CD34+ cells of 6 patients with AML 100 days after allo-HCT to identify T-cell signatures associated with either imminent relapse (REL) or durable complete remission (CR). We observed a higher frequency of cytotoxic CD8+ effector and gamma delta (γδ) T cells in CR vs REL samples. Pseudotime and gene regulatory network analyses revealed that CR CD8+ T cells were more advanced in maturation and had a stronger cytotoxicity signature, whereas REL samples were characterized by inflammatory tumor necrosis factor/NF-κB signaling and an immunosuppressive milieu. We identified ADGRG1/GPR56 as a surface marker enriched in CR CD8+ T cells and confirmed in a CD33-directed chimeric antigen receptor T cell/AML coculture model that GPR56 becomes upregulated on T cells upon antigen encounter and elimination of AML cells. We show that GPR56 continuously increases at the protein level on CD8+ T cells after allo-HCT and confirm faster interferon gamma (IFN-γ) secretion upon re-exposure to matched, but not unmatched, recipient AML cells in the GPR56+ vs GPR56– CD8+ T-cell fraction. Together, our data provide a single-cell reference map of BM–derived T cells after allo-HCT and propose GPR56 expression dynamics as a surrogate for antigen encounter after allo-HCT.Keywords
This publication has 39 references indexed in Scilit:
- Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?Blood, 2011
- Specific expression of GPR56 by human cytotoxic lymphocytesJournal of Leukocyte Biology, 2011
- Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemiaBlood, 2010
- Higher CD34+ and CD3+ Cell Doses in the Graft Promote Long-Term Survival, and Have No Impact on the Incidence of Severe Acute or Chronic Graft-versus-Host Disease after In Vivo T Cell-Depleted Unrelated Donor Hematopoietic Stem Cell Transplantation in ChildrenTransplantation and Cellular Therapy, 2010
- Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin diseaseArthritis Research & Therapy, 2007
- Human Naive CD8 T Cells Down-Regulate Expression of the WNT Pathway Transcription Factors Lymphoid Enhancer Binding Factor 1 and Transcription Factor 7 (T Cell Factor-1) following Antigen Encounter In Vitro and In VivoThe Journal of Immunology, 2006
- Molecules and mechanisms of the graft-versus-leukaemia effectNature Reviews Cancer, 2004
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- CD27: marker and mediator of T-cell activation?Immunology Today, 1994